Abstract: The present disclosure describes a disc-like apparatus and method of its use allowing for the one-step concentration and separation of therapeutic factors found in mammalian body fluid.

Abstract: The present disclosure describes a disc-like apparatus and method of its use allowing for the one-step concentration and separation of therapeutic factors found in mammalian body fluid.

Abstract: A binding syringe and methods of use are disclosed. The binding syringe includes an outer body, a middle chamber, an inner body, and a plunger. The middle chamber has an outer surface including a plurality of pores, which are configured to retain certain components from biological fluid extracted by the outer body. A method of use includes placing a binding syringe into a patient or container, actuating the binding syringe to extract biological fluid, fluid flowing through a flowpath, and binding components of the biological fluid to be removed to the binding syringe.

Abstract: A binding syringe and methods of use are disclosed. The binding syringe includes an outer body, a middle chamber, an inner body, and a plunger. The middle chamber has an outer surface including a plurality of pores, which are configured to retain certain components from biological fluid extracted by the outer body. A method of use includes placing a binding syringe into a patient or container, actuating the binding syringe to extract biological fluid, fluid flowing through a flowpath, and binding components of the biological fluid to be removed to the binding syringe.

Abstract: The present disclosure describes a disc-like apparatus and method of its use allowing for the one-step concentration and separation of therapeutic factors found in mammalian body fluid.

Abstract: Techniques and devices for removing (filtering out) unwanted/inhibitory components (for example, products, byproducts and/or cell output such as inhibitory catabolic proteins) from a composition (for example, autologous fluid or serum) containing such unwanted/inhibitory components. The devices include at least one construct designed to contain a composition (for example, autologous fluid or serum) containing inhibitory/unwanted components (products, byproducts and/or output of cells such as inhibitory catabolic proteins). The construct is provided with interior walls including specific protein capturing means designed to remove the inhibitory/unwanted component(s) (for example, specific protein(s)) from the composition. Proteins targeted for capture include, but are not limited to, catabolic cytokines such as IL-1?, IL-?, IL-6, TNF?, IFN? and MMPS as these proteins inhibit the healing process.

Abstract: Techniques and devices for removing (filtering out) unwanted/inhibitory components (for example, products, byproducts and/or cell output such as inhibitory catabolic proteins) from a composition (for example, autologous fluid or serum) containing such unwanted/inhibitory components. The devices include at least one construct designed to contain a composition (for example, autologous fluid or serum) containing inhibitory/unwanted components (products, byproducts and/or output of cells such as inhibitory catabolic proteins). The construct is provided with interior walls including specific protein capturing means designed to remove the inhibitory/unwanted component(s) (for example, specific protein(s)) from the composition. Proteins targeted for capture include, but are not limited to, catabolic cytokines such as IL-1?, IL-?, IL-6, TNF?, IFN? and MMPS as these proteins inhibit the healing process.

Abstract: Techniques and devices for removing (filtering out) unwanted/inhibitory components (for example, products, byproducts and/or cell output such as inhibitory catabolic proteins) from a composition (for example, autologous fluid or serum) containing such unwanted/inhibitory components. The devices include at least one construct designed to contain a composition (for example, autologous fluid or serum) containing inhibitory/unwanted components (products, byproducts and/or output of cells such as inhibitory catabolic proteins). The construct is provided with interior walls including specific protein capturing means designed to remove the inhibitory/unwanted component(s) (for example, specific protein(s)) from the composition. Proteins targeted for capture include, but are not limited to, catabolic cytokines such as IL-1?, IL-?, IL-6, TNF?, IFN? and MMPS as these proteins inhibit the healing process.

Abstract: Systems and methods for producing enhanced blood serum with concentrated growth factors and/or prophylactically and therapeutically active proteins. An autologous blood product is obtained from a donor and then incubated into a containment device (sterile container) that includes a source of cells or tissue (for example, autologous, allogeneic, or xenographic tissue, or combinations thereof). The cells from the injected fluid (autologous blood product) interact/incubate with the source of cells or tissue inside the containment device, to produce a serum that is loaded with autologous proteins, growth factors, and cytokines. The autologous blood product may be a fluid and/or composition that includes blood, whole blood, autologous conditioned plasma, platelet-rich plasma, platelet-poor plasma, bone marrow aspirate, bone marrow concentrate and stem cells, among others, and combinations thereof.

Abstract: A triple syringe system that allows for either a larger volume of ACP, or a larger combined output of PRP (platelet rich plasma) and PPP (platelet poor plasma). The different outputs are based upon different centrifuge spin regimes. The system of the present invention produces up to 15 mL of ACP, or 3 mL of PRP plus 25 mL of PPP. The system of the present invention solves the problem of a larger volume of ACP and with a higher cellular concentration. The multi-syringe system allows for the connection of two or more additional syringes. The fractions may be extracted with the multi-syringe system of the present invention at different sequential times, or at the same time.

Abstract: Formulations, mixtures, compositions and techniques for improved treatment options for osteoarthritis and intra-articular joint degeneration. The formulations and compositions are provided in the form of injectable aqueous formulations that increase the delivery of a lubricating agent (lubrication molecules) into the joint to resist breakdown, decrease free radical production (by neutralizing these radicals), and increase removal of superoxide byproducts in the synovial fluid. The injectable aqueous formulations are preferably administered into the intra-articular space of an intra-articular joint. The lubricating formulation includes molecules of lubricin and SOD, hyaluronic acid and SOD, or lubricin and SOD and hyaluronic acid, or hyaluronic acid and lubricin, or Vitamin E and SOD or hyaluronic acid, or combinations thereof.

Abstract: Techniques and devices for removing (filtering out) unwanted/inhibitory components (for example, products, byproducts and/or cell output such as inhibitory catabolic proteins) from a composition (for example, autologous fluid or serum) containing such unwanted/inhibitory components. The devices include at least one construct designed to contain a composition (for example, autologous fluid or serum) containing inhibitory/unwanted components (products, byproducts and/or output of cells such as inhibitory catabolic proteins). The construct is provided with interior walls including specific protein capturing means designed to remove the inhibitory/unwanted component(s) (for example, specific protein(s)) from the composition. Proteins targeted for capture include, but are not limited to, catabolic cytokines such as IL-1?, IL-?, IL-6, TNF?, IFN? and MMPS as these proteins inhibit the healing process.

Abstract: Systems and methods for producing enhanced blood serum with concentrated growth factors and/or prophylactically and therapeutically active proteins. An autologous blood product is obtained from a donor and then incubated into a containment device (sterile container) that includes a source of cells or tissue (for example, autologous, allogeneic, or xenographic tissue, or combinations thereof). The cells from the injected fluid (autologous blood product) interact/incubate with the source of cells or tissue inside the containment device, to produce a serum that is loaded with autologous proteins, growth factors, and cytokines. The autologous blood product may be a fluid and/or composition that includes blood, whole blood, autologous conditioned plasma, platelet-rich plasma, platelet-poor plasma, bone marrow aspirate, bone marrow concentrate and stem cells, among others, and combinations thereof.